Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
Business Wire•05/08/2026•07:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.
Create a free account to read the full story.